Table 1 Characteristics of the study population
From: Increased PARylation impacts the DNA methylation process in type 2 diabetes mellitus
| Â | CT | T2DM | P |
|---|---|---|---|
N | 48 | 61 | Â |
Age (years) | 60 ± 8 | 63 ± 9 | 0.065 |
Male % (n) | 48 (23) | 62 (38) | 0.1741 |
Disease duration (years) | – | 8.51 ± 7.47 |  |
BMI (kg/m2) | 26.12 ± 3.77 | 29.85 ± 5.14 |  < 0.001 |
Waist circ. (cm) | 84 ± 8.1 | 106.8 ± 11.69 |  < 0.001 |
DBP (mm Hg) | 79.09 ± 7.70 | 81.33 ± 11.08 | 0.311 |
SBP (mm Hg) | 124.76 ± 10.39 | 139.35 ± 18.65 |  < 0.001 |
FBG (mg/dl) | 88.69 ± 10.98 | 143.13 ± 41.04 |  < 0.001 |
HbA1c (%) | 5.25 ± 0.35 | 7.58 ± 1.39 |  < 0.001 |
Total cholesterol (mg/dl) | 213.18 ± 35.27 | 181.86 ± 39.56 |  < 0.001 |
LDL cholesterol (mg/dl) | 124.65 ± 30.82 | 91.29 ± 45.61 |  < 0.001 |
HDL cholesterol (mg/dl) | 64.41 ± 14.78 | 46.41 ± 11.41 |  < 0.001 |
Triglycerides (mg/dl) | 100.11 ± 33.53 | 177.56 ± 83.39 |  < 0.001 |
ALT (U/l) | 19.93 ± 6.4 | 22.67 ± 13.51 | 0.184 |
AST (U/l) | 21.37 ± 5.0 | 19.42 ± 8.49 | 0.154 |
GGT (U/l) | 16.94 ± 5.79 | 28.51 ± 21.4 | 0.004 |
Total bilirubin (mg/dl) | 0.57 ± 0.06 | 0.58 ± 0.27 | 0.929 |
Direct bilirubin (mg/dl) | 0.19 ± 0.01 | 0.22 ± 0.008 | 0.624 |
Creatinine (mg/dl) | 0.89 ± 0.17 | 0.9 ± 0.32 | 0.744 |
MALB (mg/l) | – | 24.95 ± 29.61 |  |
PAR (pg/ml) | 63.96 ± 38.04 | 108.38 ± 70.57 | 0.001 |
5mC (%) | 0.566 ± 0.185 | 0.679 ± 0.246 | 0.144 |
5hmC (%) | 0.037 ± 0.009 | 0.070 ± 0.037 |  < 0.001 |
5fC (%) | 0.002 ± 0.002 | 0.006 ± 0.006 | 0.001 |
Insulin treated % (n) | – | 28 (17) |  |
Metformin treated % (n) | – | 54 (33) |  |
Incretins treated % (n) | – | 28 (17) |  |